How did FBIO's Q1 2025 EPS forecast compare to past trends?

**Fortress Biotech's (FBIO) Q1 2025 EPS forecast is not currently available**, and the company's recent past performance shows fluctuations in both revenue and earnings.

1. **Q4 2024 Performance**: FBIO reported a quarterly loss of $0.26 per share for Q4 2024, which is an improvement from the $0.53 per share loss in Q1 2023. However, it missed the Zacks Consensus Estimate of a loss of $0.79, indicating expectations were not fully met.

2. **Trends and Challenges**: FBIO has faced challenges in profitability and cash flow, evidenced by a negative P/E ratio of -0.65 and a negative earnings yield of -1.54%. The company's debt-to-equity ratio stands at 3.38, indicating a high level of debt compared to equity. Despite these challenges, FBIO's price-to-sales ratio is 0.74, and its enterprise value to sales ratio is 0.94, suggesting valuation relative to sales.
3. **Insider Activity**: There has been some insider buying activity, with CEO and Chairman ROSENWALD LINDSAY A MD acquiring 50,000 shares in January 2024, which could indicate confidence in the company's future performance.
4. **Revenue and Earnings Estimates**: FBIO's revenue estimates for Q1 2025 are not currently available. However, the full-year 2024 revenue was expected to be $58.85 million, with earnings expected to be -$3.22 per share. This suggests that FBIO is facing significant challenges in achieving profitability in the near term.

In conclusion, FBIO's Q1 2025 EPS forecast is not currently available, but the company's recent performance indicates ongoing challenges in achieving profitability. The company's debt levels and negative earnings yield suggest that FBIO is facing significant headwinds, although insider buying activity may provide some optimism for the future.